Dianthus Therapeutics, Inc. (DNTH) stock
DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31
$92.48+3.18 (+3.56%)
Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%
Dianthus Therapeutics cash
Cash and short-term investments held at the end of each period.
Dianthus Therapeutics's cash was $54.08M at Sep 30, 2026. For fiscal 2025 it was $50.25M, up 129.0% from the year before. Over ten years it grew 58.6% a year on average. The highest annual figure on record is $150.62M in fiscal 2020.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.25M | +129.0% |
| FY2024 | Dec 31, 2024 | $21.95M | -83.3% |
| FY2023 | Dec 31, 2023 | $131.19M | +73.7% |
| FY2022 | Dec 31, 2022 | $75.55M | +42.8% |
| FY2021 | Dec 31, 2021 | $52.91M | -64.9% |
| FY2020 | Dec 31, 2020 | $150.62M | +2.1% |
| FY2019 | Dec 31, 2019 | $147.51M | +2.2% |
| FY2018 | Dec 31, 2018 | $144.35M | +179.9% |
| FY2017 | Dec 31, 2017 | $51.57M | +1035.1% |
| FY2016 | Dec 31, 2016 | $4.54M | +808.6% |
| FY2015 | Dec 31, 2015 | $500.00K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $54.08M | -1.7% |
| Q2 FY2026 | Jun 30, 2026 | $107.61M | +800.4% |
| Q1 FY2026 | Mar 31, 2026 | $617.11M | +6568.6% |
| Q4 FY2025 | Dec 31, 2025 | $50.25M | +129.0% |
| Q3 FY2025 | Sep 30, 2025 | $54.99M | -80.4% |
| Q2 FY2025 | Jun 30, 2025 | $11.95M | -96.7% |
| Q1 FY2025 | Mar 31, 2025 | $9.25M | -97.5% |
| Q4 FY2024 | Dec 31, 2024 | $21.95M | -83.3% |
| Q3 FY2024 | Sep 30, 2024 | $281.12M | +48.1% |
| Q2 FY2024 | Jun 30, 2024 | $360.71M | +553.0% |
| Q1 FY2024 | Mar 31, 2024 | $377.04M | +612.8% |
| Q4 FY2023 | Dec 31, 2023 | $131.19M | +73.7% |
| Q3 FY2023 | Sep 30, 2023 | $189.87M | +78.9% |
| Q2 FY2023 | Jun 30, 2023 | $55.24M | -60.9% |
| Q1 FY2023 | Mar 31, 2023 | $52.90M | -66.6% |
| Q4 FY2022 | Dec 31, 2022 | $75.55M | +42.8% |
| Q3 FY2022 | Sep 30, 2022 | $106.14M | -45.4% |
| Q2 FY2022 | Jun 30, 2022 | $141.21M | -32.6% |
| Q1 FY2022 | Mar 31, 2022 | $158.38M | +18.1% |
| Q4 FY2021 | Dec 31, 2021 | $52.91M | -64.9% |
| Q3 FY2021 | Sep 30, 2021 | $194.40M | +18.9% |
| Q2 FY2021 | Jun 30, 2021 | $209.59M | +17.6% |
| Q1 FY2021 | Mar 31, 2021 | $134.07M | +1.4% |
| Q4 FY2020 | Dec 31, 2020 | $150.62M | +2.1% |
| Q3 FY2020 | Sep 30, 2020 | $163.51M | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $178.28M | +2.4% |
| Q1 FY2020 | Mar 31, 2020 | $132.19M | +2.4% |
| Q4 FY2019 | Dec 31, 2019 | $147.51M | +2.2% |
| Q3 FY2019 | Sep 30, 2019 | $162.35M | +0.5% |
| Q2 FY2019 | Jun 30, 2019 | $174.05M | -0.8% |
| Q1 FY2019 | Mar 31, 2019 | $129.09M | +211.3% |
| Q4 FY2018 | Dec 31, 2018 | $144.35M | +179.9% |
| Q3 FY2018 | Sep 30, 2018 | $161.62M | +169.6% |
| Q2 FY2018 | Jun 30, 2018 | $175.37M | +175.0% |
| Q1 FY2018 | Mar 31, 2018 | $41.46M | +812.7% |
| Q4 FY2017 | Dec 31, 2017 | $51.57M | – |
| Q3 FY2017 | Sep 30, 2017 | $59.95M | – |
| Q2 FY2017 | Jun 30, 2017 | $63.78M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.54M | – |
See a number that looks wrong?